Application of a biomarker for predicting temozolomide resistance

A biomarker, temozolomide technology, applied in the field of biomarkers, can solve problems such as poor curative effect, achieve good predictive value, feasible method, and simple operation steps

Active Publication Date: 2021-03-16
辽宁省肿瘤医院
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] The purpose of the present invention is to overcome the above-mentioned shortcomings of the existing glioma treatment, provide plasma GPBB as a biomarker for predicting glioma drug resistance to temozolomide, and aim to solve the problem of poor curative effect caused by primary drug resistance of temozolomide

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of a biomarker for predicting temozolomide resistance
  • Application of a biomarker for predicting temozolomide resistance
  • Application of a biomarker for predicting temozolomide resistance

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0047] 1. Materials and methods

[0048] 1.1 Sample collection

[0049] The sample collection in this case was assisted by neurosurgeons from Liaoning Cancer Hospital. Samples were collected before surgery, and glioma resection was performed, and histopathology was diagnosed as high-grade glioma according to WHO grade III or IV. In addition, the tissues were tested for sensitivity to temozolomide by Collagen gel droplet embedded culture drug sensitivity test (CD-DST). The patient was treated with temozolomide. According to the above criteria, 63 patients with high-grade glioma were screened in this case as the research objects, and the detailed phenotype information of the above 63 enrolled patients was registered, and their medical history, family history, IDH1 mutation, 1p / 19q co-deletion and MGMT promoter methylation status, etc., and all signed informed consent. This invention was approved by the Ethics Committee of Liaoning Cancer Hospital (approval number: No. 20150...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
wavelengthaaaaaaaaaa
wavelengthaaaaaaaaaa
Login to view more

Abstract

The invention discloses application of a biomarker for predicting temozolomide resistance, and belongs to the technical field of biomarkers. Through the biomarker for detecting the resistance to a glioma treating medicine temozolomide by an ELISA technology, plasma GPBB can predict the resistance to the temozolomide in high-grade glioma patient, especially has a better predictive value in an IDH1mutation patient. The biomarker can be applied to prediction of the temozolomide resistance in glioma treatment, and the found biomarker GPBB helps to formulate a precise medicine delivering scheme for the glioma treatment. In addition, the biomarker is high in sensitivity and high in specificity and has the AUC up to 83.5%. Through use of a plasma sample as a biomarker detection sample, the advantages of a feasible, scientific and reasonable method, convenience in material obtainment, simple operation steps, continuous dynamic detection and the like are achieved.

Description

technical field [0001] The invention belongs to the field of biomarkers, and in particular relates to the application of GPBB (glycogen phosphorylase BB) in glioma plasma as a biomarker for predicting temozolomide drug resistance. Background technique [0002] Gliomas are one of the common intracranial tumors, accounting for more than 32% of central nervous system tumors, more than half of which are malignant gliomas, with an annual incidence of about 3.5-4.5 per 100,000 population. Since the NCCN guidelines proposed the comprehensive treatment of surgery combined with adjuvant radiotherapy and chemotherapy as the standard treatment strategy for malignant glioma, the treatment effect has been improved to some extent, but the overall survival benefit is still not optimistic. Studies have reported that the median survival time of malignant glioma treated with postoperative adjuvant chemotherapy combined with whole brain radiotherapy is only 12-15 months, and the five-year surv...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): G01N33/573G01N33/574
CPCG01N33/573G01N33/57484
Inventor 徐君南张烨孙涛
Owner 辽宁省肿瘤医院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap